Literature DB >> 3731542

Circulating immune complexes in patients with acquired immune deficiency syndrome contain the AIDS-associated retrovirus.

W J Morrow, M Wharton, R B Stricker, J A Levy.   

Abstract

Using the polyethylene glycol (PEG) precipitation technique, circulating immune complexes were demonstrated in 88% of patients with acquired immune deficiency syndrome (AIDS) and AIDS-related disorders. The finding of immune complexes in these individuals was confirmed by using a second assay, the commercially available Clq-IgG enzyme-linked immunosorbent assay kit. The material precipitated by PEG contained elevated levels of IgG, IgM, Clq, and C3. There was no substantial correlation between the level of IgG in the complexes and the serum IgG concentration, although there was a significant association between complexed IgG and the titer of anti-AIDS-associated retrovirus (ARV) antibody in the serum. In some precipitates, ARV antigens were detected by immunoblot analysis. Coculture of other precipitates with normal lymphocytes revealed the presence of infectious virus. These data confirm the existence of immune complexes in the sera of AIDS patients and indicate that in some cases they may comprise ARV and anti-ARV antibodies.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3731542     DOI: 10.1016/0090-1229(86)90196-0

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  33 in total

1.  B lymphocytes in lymph nodes and peripheral blood are important for binding immune complexes containing HIV-1.

Authors:  J J Jakubik; M Saifuddin; D M Takefman; G T Spear
Journal:  Immunology       Date:  1999-04       Impact factor: 7.397

2.  CD4-Negative cells bind human immunodeficiency virus type 1 and efficiently transfer virus to T cells.

Authors:  G G Olinger; M Saifuddin; G T Spear
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

3.  IgA1 is the major immunoglobulin component of immune complexes in the acquired immune deficiency syndrome.

Authors:  S Jackson; L M Dawson; D P Kotler
Journal:  J Clin Immunol       Date:  1988-01       Impact factor: 8.317

4.  Serum non-organ specific autoantibodies in human immunodeficiency virus 1 infection.

Authors:  F Cassani; L Baffoni; E Raise; L Selleri; M Monti; L Bonazzi; F M Gritti; F B Bianchi
Journal:  J Clin Pathol       Date:  1991-01       Impact factor: 3.411

Review 5.  Role of complement and Fc receptors in the pathogenesis of HIV-1 infection.

Authors:  D C Montefiori
Journal:  Springer Semin Immunopathol       Date:  1997

6.  Antigen detection in primary HIV infection.

Authors:  M von Sydow; H Gaines; A Sönnerborg; M Forsgren; P O Pehrson; O Strannegård
Journal:  Br Med J (Clin Res Ed)       Date:  1988-01-23

7.  Serum and effector-cell antibody-dependent cellular cytotoxicity (ADCC) activity remains high during human immunodeficiency virus (HIV) disease progression.

Authors:  E Ojo-Amaize; P G Nishanian; D F Heitjan; A Rezai; I Esmail; E Korns; R Detels; J Fahey; J V Giorgi
Journal:  J Clin Immunol       Date:  1989-11       Impact factor: 8.317

8.  Immunoglobulin and complement complexes in blood following infection with human immunodeficiency virus type 1.

Authors:  X X Peng; M A Wainberg; Y Tao; B G Brenner
Journal:  Clin Diagn Lab Immunol       Date:  1996-01

9.  Predictors of survival in human immunodeficiency virus type 1-seropositive intravenous drug users.

Authors:  J B Page; S Lai; M A Fletcher; R Patarca; P C Smith; H C Lai; N G Klimas
Journal:  Clin Diagn Lab Immunol       Date:  1996-01

Review 10.  Pathogenesis of human immunodeficiency virus infection.

Authors:  J A Levy
Journal:  Microbiol Rev       Date:  1993-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.